Description of the molecular and clinical characteristics of the mucopolysaccharidosis type VII Iberian cohort

Orphanet J Rare Dis. 2021 Oct 22;16(1):445. doi: 10.1186/s13023-021-02063-1.

Abstract

Background: Mucopolysaccharidosis type VII (Sly syndrome) is an ultra-rare neurometabolic disorder caused by inherited deficiency of the lysosomal enzyme β-glucuronidase. Precise data regarding its epidemiology are scarce, but birth prevalence is estimated to vary from 0.02 to 0.24 per 100,000 live births. The clinical course and disease progression are widely heterogeneous, but most patients have been reported to show signs such as skeletal deformities or cognitive delay. Additionally, detection criteria are not standardized, resulting in delayed diagnosis and treatment.

Methods: We present a cohort of 9 patients with mucopolysaccharidosis VII diagnosed in the Iberian Peninsula, either in Spain or Portugal. The diagnostic approach, genetic studies, clinical features, evolution and treatment interventions were reviewed.

Results: We found that skeletal deformities, hip dysplasia, hydrops fetalis, hepatosplenomegaly, hernias, coarse features, respiratory issues, and cognitive and growth delay were the most common features identified in the cohort. In general, patients with early diagnostic confirmation who received the appropriate treatment in a timely manner presented a more favorable clinical evolution.

Conclusions: This case series report helps to improve understanding of this ultra-rare disease and allows to establish criteria for clinical suspicion or diagnosis, recommendations, and future directions for better management of patients with Sly syndrome.

Keywords: MPS VII; Mucopolysaccharidosis; Rare disease; Sly syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Europe
  • Humans
  • Mucopolysaccharidosis VII* / diagnosis
  • Mucopolysaccharidosis VII* / genetics
  • Portugal
  • Spain